Figure 8.

Magnoflorine suppresses osteoclast differentiation via the NF-κB pathway. (A) BMMs were pretreated for 4 h without or with 200 µM magnoflorine and then treated with 50 ng/ml RANKL for the indicated time points. Nuclear protein was isolated and analyzed by Western blot with specific antibodies against NF-κB p65 and p-NF-κB p65. (B, C) The levels of phosphorylated and total NF-κB p65 were quantified and normalized to histone H3. (D–F) BMMs were stimulated for 0, 1, 3, and 5 days with M-CSF (30 ng/ml) and RANKL (50 ng/ml) with or without 200 µM magnoflorine, and protein levels of c-Fos and NFATc1 in cell lysates, normalized to that of β-actin, were measured. Data are presented as mean ± SD (*P < 0.05, **P < 0.01, ***P < 0.001).